Q1 earnings beat expectations, mainly due to improved execution in BioScience and Medtech products, VWR Distribution and Services have stabilized, but organic revenue declined 5% year-over-year. The company reiterates full-year guidance, expecting recovery in H2.

Key data: Total revenue of $1.581 billion, organic decline of 4% year-over-year; adjusted EPS of $0.17, above expectations; VWR revenue of $1.15 billion, organic decline of 5%; BMP revenue of $431 million, organic decline of 2%, but process chemicals recorded double-digit organic growth.

Business progress: The Revival plan has shown early results, with approximately 25% of the executive team refreshed, and the addition of a Chief Digital Officer and Chief Transformation Officer. Q1 completed more than 8 weeks of lean improvement activities, and 12 capital projects were approved. After the upgrade, VWR's e-commerce platform saw improvements in traffic, conversion rate, and revenue. BMP's book-to-bill ratio exceeded 1.1x, with particularly strong orders for process chemicals, operational stability improved, and backlog declined slightly.

Guidance & outlook: Reiterates full-year guidance, expecting Q2 adjusted EPS of $0.19–$0.20. VWR growth bottomed in Q1, expected to turn positive in H2; BMP growth will bottom in Q2, as the comparison effect from unusual customer orders widens the Q2 year-over-year decline by more than 500 basis points. The Middle East conflict brings an additional inflation pressure of approximately $10–20 million, which has been incorporated into guidance.

Risk/Highlight signals: Management tone is positive, emphasizing that "the company is turning a corner," with Revival improving execution and operations; however, caution is warranted regarding weak European markets and the potential impact of Middle East inflation on H2 costs.